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continuous positive airway pressure therapy on
outcomes in patients with atrial
fibrillation—Results from the Outcomes Registry
for Better Informed Treatment of Atrial
Fibrillation (ORBIT-AF)
Fredrik Holmqvist, MD, PhD,a Ni Guan, MS,a Zhaoyin Zhu, MS,a Peter R. Kowey, MD,b Larry A. Allen, MD, MHS,c Gregg C.
Fonarow, MD,d Elaine M. Hylek, MD, MPH, e Kenneth W. Mahaffey, MD, f James V. Freeman, MD, MPH, MS, g
Paul Chang, MD, h DaJuanicia N. Holmes, MS, a Eric D. Peterson, MD, MPH, a Jonathan P. Piccini, MD, MHS, a
and Bernard J. Gersh, MB, ChB, DPhil i, on behalf of the ORBIT-AF Investigators Durham, NC; Philadelphia, PA;
Aurora, CO; Los Angeles, Stanford, CA; Boston, MA; New Haven, CT; Raritan, NJ; and Rochester, MNBackground Obstructive sleep apnea (OSA) is common in patients with atrial fibrillation (AF). Little is knownabout the impact
of OSA on AF treatment and long-term outcomes.We studied whether patients with OSA have a greater likelihood of progressing to
more persistent forms of AF or require more hospitalizations and/or worse outcomes compared with patients without OSA.
Methods A total of 10,132 patients were enrolled between June 2010 and August 2011 in the Outcomes Registry for Better
Informed Treatment of Atrial Fibrillation (ORBIT-AF) and followed for up to 2 years. The prevalence of OSA and continuous positive
airway pressure (CPAP) treatment was captured at baseline. The association between OSA and major cardiovascular outcomes
was analyzed using multivariable hierarchical logistic regression modeling and Cox frailty regression model.
Results Of the 10,132 patients with AF, 1,841 had OSA. Patients with OSA were more symptomatic (22% vs 16%
severe/disabling symptoms; P b .0001) and more often on rhythm control therapy (35% vs 31%; P = .0037). In adjusted
analyses, patients with OSA had higher risk of hospitalization (hazard ratio [HR], 1.12; 95% CI, 1.03-1.22; P = .0078), but
no difference in the risks of death (HR, 0.94; 95% CI, 0.77-1.15; P = .54); the composite of CV death, myocardial infarction,
and stroke/transient ischemic attack (HR, 1.07; 95% CI, 0.85-1.34; P = .57); major bleeding (HR, 1.18; 95% CI, 0.96-1.46;
P = .11); or AF progression (HR, 1.06; 95% CI, 0.89-1.28; P = .51). Patients with OSA on CPAP treatment were less likely to
progress to more permanent forms of AF compared with patients without CPAP (HR, 0.66; 95% CI, 0.46-0.94; P = .021).
Conclusion Compared with those without, AF patients with OSA have worse symptoms and higher risks of
hospitalization, but similar mortality, major adverse cardiovascular outcome, and AF progression rates.
Clinical Trial Registration: NCT01165710 (http://www.clinicaltrials.gov). (Am Heart J 2015;169:647-654.e2.)
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(h
hObstructive sleep apnea (OSA) has been shown to be
independently associated with increased cardiovascular
morbidity, including hypertension, congestive heart
failure, ischemic heart disease, and stroke.1–3 Patients
with OSA have a higher prevalence of atrial fibrillation
(AF) than patients without OSA,4–7 and patients with OSA
are more likely to develop new-onset AF, independent of
obesity.7 Obstructive sleep apnea is also associated with
an increased risk of AF after coronary bypass surgery,
higher recurrence rates of AF after cardioversion, and
higher relapse rates of AF after AF catheter ablation.8–16
Although patients with OSA have been shown to have
higher rates of cardiovascular morbidity than patients
without OSA,1,2 whether ambulatory patients with AF
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May 2015and OSA experience greater AF progression or worse
outcomes than those without OSA remains unknown.
Furthermore, although preliminary data indicate that
continuous positive airway pressure (CPAP) treatment
may be associated with lower recurrence rates of AF after
cardioversion,14 the broader impact of CPAP treatment
on outcomes in patients with AF is largely unknown.
Therefore, the objectives of this study were (1) to define
the frequency of diagnosed OSA among a nationwide AF
population; (2) to determine whether OSA is associated
with worse outcomes including hospitalizations, AF
complications, and survival; (3) to characterize whether
OSA is associated with arrhythmic progression of AF; and
(4) to determine whether CPAP treatment is associated
with outcomes in patients with AF and OSA.Methods
The Outcomes Registry for Better Informed Treatment
of Atrial Fibrillation (ORBIT-AF) is a contemporary
registry of outpatients in the United States with AF. Its
design has been described in detail elsewhere.17 In brief,
a nationally representative sample of sites was invited to
participate, and an adaptive design was used to ensure
provider and geographic heterogeneity. Consecutive
patients with AF meeting the inclusion criteria (at least
18 years of age, electrocardiographic evidence of AF,
providing informed consent) and none of the exclusion
criteria (life expectancy of b6 months or AF secondary to
reversible conditions) were enrolled.
Data collection included demographics, past medical
history, type of AF and prior interventions, ongoing
antithrombotic therapy, vital signs, laboratory studies,
and electrocardiographic and echocardiographic findings.
The prevalence of clinician-defined OSA (ie, diagnosis or
history of OSA) at baseline and CPAP treatment (“currently
undergoing CPAP therapy”) was captured. In ORBIT-AF,
follow-up data collection occurs at 6-month intervals for a
minimum of 2 years. Two-year outcomes were analyzed in
this cohort study.
Paroxysmal AF was defined as recurrent AF episodes
that terminate spontaneously within 7 days; persistent AF
as recurrent AF that is sustained for more than 7 days; and
permanent AF as AF in which the presence of the AF is
accepted.18 Progression in AF type was considered as a
binary outcome (either “the same/better” or “worsening”);
worsening was defined as (1) paroxysmal AF at baseline
(or “first detected/newonset”AFbecoming paroxysmal AF
at next available follow-up) becoming persistent or
permanent at the last follow-up visit or (2) persistent AF
at baseline (or “first detected/new onset” AF becoming
persistent AF at next available follow-up) becoming
permanent at the last follow-up visit.19
The baseline ORBIT-AF population included 10,132
patients enrolled between June 2010 and August 2011
from 176 sites. Data on CPAP treatment were lacking in 4patients, yielding a study population of 1,837 patients
with OSA for the analyses regarding CPAP. For the
outcomes analysis for patients with OSA vs patients
with no OSA, patients without any follow-up data were
excluded (n = 490). For the outcomes analysis for CPAP
treatment vs no CPAP treatment, patients without any
follow-up data (n = 78) and patients from sites with less
than 6 patients were excluded (n = 135) from the
analysis. Sites with less than 6 patients were excluded
because these sites had too little information to make
within-site comparisons and therefore caused model
convergence problems. The exclusion was necessary
for the adjusted analysis and was implemented in the
unadjusted analysis as well, for consistency. Data are
presented as frequencies and percentages for categorical
variables and medians (interquartile range) for continu-
ous variables. Groups are compared using the χ2 test for
categorical variables and the Wilcoxon rank sum test for
continuous variables.
To examine both the unadjusted and adjusted associ-
ation between OSA and each of the 4 outcomes (all-cause
death; first all-cause hospitalization; the composite of first
event of cardiovascular death, stroke/non–central ner-
vous system embolism, transient ischemic attack [TIA], or
myocardial infarction; first major bleed) within 2 years of
baseline enrollment in the registry, a multivariable Cox
frailty regression model that accounts for the variability in
outcomes between sites was used. For each outcome,
backward selection with stay criteria of P b .05 for
candidate variables, a prespecified candidate variable list
was performed on the first imputed dataset to construct
the Cox frailty regression model. All continuous variables
were evaluated for nonlinearity with the outcome, and
those that did not meet the linear relationship criteria (P b
.05) were accounted for using linear splines. Missing data
were multiply imputed, and final estimates and standard
errors reflect the combined analysis over 5 imputed
datasets. For AF progression, a multivariable hierarchical
logistic regression model was fit including site as a random
effect. The samemodel constructionmethod described for
the aforementioned outcomes was used to construct the
model for AF progression. Hazard ratio/odds ratio (HR/OR)
with corresponding 95% CI and P value are presented.
To explore the CPAP treatment effect in OSA on
outcomes, the treatment effect was adjusted for treat-
ment selection bias via propensity score stratification.
The predicted probability of receiving treatment for
individuals, given their patient characteristics and site
participation, was obtained. Because site was included as
a fixed effect to obtain the propensity scores, we
excluded patients from small sites (patients from sites
with b6 patients) from the analysis to obtain stable
estimates. The propensity scores were then stratified into
quintiles. These quintiles formed strata in the final Cox
proportional hazard model that accounted for variability
in outcomes between sites for all the outcomes except
Table I. Baseline characteristics by OSA
Overall No OSA OSA
P(N = 10,132) (n = 8291) (n = 1841)
Age, y 75 (67-82) 76 (68-82) 69 (62-77) b.0001
Male 58 55 69 b.0001
Race
White 89 89 88 .0004
Black or African American 5.0 4.6 6.7
Hispanic 4.2 4.4 3.2
Other 1.4 1.4 1.5
Medical history
Hypertension 83 82 87 b.0001
Hyperlipidemia 72 71 76 b.0001
Diabetes 29 27 42 b.0001
Chronic obstructive pulmonary disease 16 15 25 b.0001
Prior myocardial infarction 16 16 16 .69
Heart failure 33 31 40 b.0001
Valvular disease 25 26 22 .0002
Peripheral vascular disease 13 13 13 .91
Prior cerebrovascular events 16 16 16 .76
Stroke (all-cause) 8.9 9.0 8.3 .36
Nonhemorrhagic 8.0 8.1 7.2 .21
Hemorrhagic 0.8 0.8 0.8 .99
Other intracranial bleeding 0.9 1.0 0.8 .41
Gastrointestinal bleeding 9.0 8.8 10 .0343
Cognitive impairment or dementia 3.1 3.1 2.9 .60
Frailty 5.8 6.1 4.3 .0029
Smoking 48 47 55 b.0001
Alcohol abuse 4.0 3.7 5.5 .0004
BMI, kg/m2 29 (25-34) 28 (25-32) 34 (29-40) b.0001
Systolic blood pressure, mm Hg 126 (116-138) 126 (116-138) 125 (116-136) .85
Diastolic blood pressure, mm Hg 72 (66-80) 72 (66-80) 73 (68-80) .0033
Left ventricular ejection fraction N50% 70 70 72 .96
Left atrial diameter, cm 4.4 (3.9-5.0) 4.4 (3.9-5.0) 4.6 (4.1-5.1) b.0001
Continuous variables are presented as median and inter-quartile range.
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outcome, the quintiles formed strata in a logistic
regression model that was fit by generalized estimating
equations with a compound symmetric correlation
structure to reflect clustering within sites. Both unadjust-
ed and adjusted HR/OR were obtained using methods to
account for clustering within sites. Corresponding 95% CI
and P value are presented for the association between
CPAP and outcomes. The list of candidate variables for all
analyzed outcomes is provided in the online Appendix
Supplementary material.
All statistical analyses of the aggregate, deidentified data
were performed by the Duke Clinical Research Institute
using SAS software (version 9.3, SAS Institute, Cary, North
Carolina). All P values were 2 sided. The Duke Clinical
Research Institute was the central coordinating and
statistical center for the ORBIT-AF registry, to which
deidentified data were sent from the sponsor for
statistical analysis. The ORBIT-AF Registry is approved
by the Duke Institutional Review Board (approval
number Pro00017596), and all participating sitesobtained institutional review board approval pursuant
to local requirements. All subjects provided written,
informed consent.
Sources of funding
The ORBIT-AF registry is sponsored by Janssen Scientific
Affairs, LLC, Raritan, NJ.Results
Of 10,132 patients enrolled in ORBIT-AF, 18% (n =
1,841) had OSA at baseline. Table I shows the baseline
characteristics overall and by the presence of OSA.
Patients with OSA were younger (69 [62-77] vs 76 [68-82]
years; P b .0001), more often male (69% vs 55%; P b
.0001), and had more comorbidities than patients
without OSA, including a greater frequency of a history
of heart failure, hypertension, diabetes, and hyperlipid-
emia. Patients with OSA were more likely to have a
history of smoking and had a higher prevalence of
chronic obstructive pulmonary disease. The body mass
Table II. Atrial fibrillation history by OSA
Overall No OSA OSA
P(N = 10,132) (n = 8291) (n = 1841)
AF type
First detected/new onset 4.7 5.0 3.7 .043
Paroxysmal 51 51 50
Persistent 17 17 18
Permanent 28 28 28
Family history of AF 15 14 17 .0091
Duration of AF diagnosis, m 47 (17-93) 47 (17-94) 46 (18-91) .92
Sinus rhythm on most recent ECG 33 33 34 .93
EHRA symptom level
No symptoms 38 39 33 b.0001
Mild 45 45 45
Severe 15 14 19
Disabling 1.8 1.7 2.7
CHADS2 risk groups
0 6.4 6.6 5.3 .73
1 22 22 23
≥2 72 72 72
CHA2DS2-VASc score (mean ± SD) 3.9 ± 1.8 4.0 ± 1.8 3.7 ± 1.8 b.0001
Prior treatment
Oral anticoagulation therapy 82 81 85 b.0001
Antiarrhythmic drug 45 44 52 b.0001
Prior cardioversions 30 28 38 b.0001
Prior catheter ablation of AF 5.5 5.0 7.7 b.0001
Current treatment
Oral anticoagulation therapy 76 75 79 .0020
Antiarrhythmic drug 29 28 33 b.0001
Rhythm strategy 32 31 35 .0037
Continuous variables are presented as median and inter-quartile range. Abbreviation: EHRA, European Heart Rhythm Association
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patients without OSA (34 [29-40] vs 28 [25-32] kg/m2; P b
.0001), their left atria larger (left atrial diameter, 4.6
[4.1-5.1] vs 4.4 [3.9-5.0] cm; P b .0001), and the diastolic
blood pressure higher.
Table II summarizes the baseline AF characteristics.
Patients with OSA were more symptomatic than patients
without OSA (22% vs 16% with severe or disabling
symptoms; P b .0001). Patients with OSA were more
frequently managed with a rhythm-control strategy (35% vs
31%; P = .0037) and consequently were more frequently
taking an antiarrhythmic drug (33%vs 28%;P b .0001). They
were alsomore likely to have a history of prior cardioversion
(38% vs 28%; P b .0001). There was no difference in the
percentage of patients with or without OSA in sinus rhythm
on baseline ECG (34% vs 33%; P = .93). Despite similar
CHADS2 score, patients with OSA were more often
receiving anticoagulation prophylaxis at baseline (79% vs
75%; P = .0020).
Table III summarizes the associations between the
outcome variables and OSA. Patients with OSA had higher
risk of hospitalization during 2-year follow-up (43 vs 35
events/100 patient-years during follow-up among patients
without OSA; adjusted HR, 1.12; 95% CI, 1.03-1.22; P =.0078). In contrast, the risk of death and the composite of
cardiovascular death, myocardial infarction, and stroke/TIA
aswell asmajor bleedingwere similar in both groups.During
follow-up, AF progression occurred in 221 (18% of patients
with nonpermanent AF at baseline) of the patients with OSA
and 984 (18%) of the patients without OSA (adjusted HR,
1.06; 95% CI, 0.89-1.28; P = .51).
Table IV and Figure summarizes the associations
between the outcome variables and CPAP treatment in
patients with OSA. Of the patients with OSA, 1,067 (58%)
were treated with CPAP. Patients with CPAP treatment
were younger (68 [62-76] vs 71 [64-78] years; P b .0001),
more often male (72% vs 64%; P = .0004), and had a
higher BMI (36 [31-41] vs 32 [28-38] kg/m2; P b .0001)
than patients without CPAP treatment. Furthermore, they
more often had diabetes mellitus (44% vs 39%; P = .043),
but the prevalence of valvular disease was lower (20% vs
24%; P = .042).
In unadjusted and adjusted analyses of patients with
OSA, no significant difference in risk was observed
between patients on CPAP treatment compared with
those not on CPAP for most of the outcomes. The one
exception was that a smaller proportion of the patients
on CPAP treatment progressed in their AF (16% of patients
Table III. Association of OSA and 2-year outcomes
Outcome
OSA (n = 1763) No OSA (n = 7879)
Unadjusted HR
(95% CI) P
Adjusted HR
(95% CI) P
No. of events
(events/100 patient-years)
No. of events
(events/100 patient-years)
All-cause death 127 (4.45) 672 (5.35) 0.83 (0.68-1.01) .057 0.94 (0.77-1.15) .54
First hospitalization
(all-cause)
866 (43.3) 3,324 (35.0) 1.17 (1.09-1.27) b.0001 1.12 (1.03-1.22) .0078
CV death, MI,
stroke/TIA
106 (3.77) 494 (3.99) 0.96 (0.75-1.15) .51 1.07 (0.85-1.34) .57
Major bleeding 123 (4.47) 463 (3.79) 1.18 (0.96-1.44) .12 1.18 (0.96-1.46) .11
Outcome
OSA (n = 1223) No OSA (n = 5349)
Unadjusted OR
(95% CI) P
Adjusted OR
(95% CI) PNo. of events (percent) No. of events (percent)
Progression of AF type 221 (18) 984 (18) 1.05 (0.88-1.24) .60 1.06 (0.89-1.28) .51
Adjusted HRs are calculated using Cox frailty models for all outcomes except the association between OSA and progression of AF, where logistic regression was used to calculate the
associated OR. Abbreviation: CV, Cardiovascular; MI, myocardial infarction.
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Volume 169, Number 5with nonpermanent AF at baseline) compared with the
patients not on CPAP treatment (18%; adjusted HR, 0.66;
95% CI, 0.46-0.94; P = .021).Discussion
Nearly 1 in 5 patients with AF in ORBIT-AF carries a
diagnosis of OSA. Patients with OSA have worse
functional status and slightly higher risks of hospitaliza-
tion, but similar rates of mortality, AF progression,
and major adverse cardiovascular events as patients
without OSA. No major differences in hospitalization or
cardiovascular outcomes were observed between patients
with OSA with or without CPAP treatment; however,
AF progression was less common in patients treated
with CPAP.
Although a large proportion of patients in ORBIT-AF had
diagnosed OSA, the observed 18% is substantially lower
than reported in some of the previously published
literature on both AF and non-AF populations.6 This may
reflect the fact that ORBIT-AF relies entirely on a history of
previously diagnosed OSA; the true prevalence may well
have been higher if all patients had been screened with
standardized criteria or routine polysomnography. How-
ever, it is also possible that the observed prevalence in the
ORBIT-AF population more accurately reflects a commu-
nity-based unselected AF patient population. Not surpris-
ingly, patients withOSA in this studyweremore frequently
male and had a substantially higher BMI than patients
without OSA, consistent with the knownmajor risk factors
for OSA.5,20 In addition, a higher prevalence of several
diseases (eg, hypertension, congestive heart failure,
diabetes) was seen in patients with OSA, compatible with
the previously described increased prevalence of cardio-
vascular diseases in patients with OSA.1,2,21Patients with AF have an increased risk of OSA and vice
versa.4–7 Although OSA and AF have many common risk
factors, OSA is an important predictor of new-onset AF,
independent of comorbid conditions including obesity.7,22
Similarly, obesity alone is associatedwith a higher risk of AF
progression (paroxysmal to permanent).22 Moreover, OSA
has also been shown to be associated with more recurrent
and symptomatic AF.13–16 Indicative of amore “aggressive”
form of AF, patients with OSA in this study were more
symptomatic, had a history of more previous cardiover-
sions and catheter ablations, and more often had been or
were currently receiving antiarrhythmic drugs and rhythm
control strategy. Despite more frequent use of ablation,
antiarrhythmic medications, and the rhythm control
strategy, there were no differences in the rates of sinus
rhythm at baseline or AF progression during follow-up
between patients with and without OSA.
Although patients with OSA have been shown to
have higher rates of cardiovascular morbidity than
patients without OSA,1,2 longitudinal outcomes in
patients with AF and OSA are lacking. In this study,
patients with OSA did have a higher risk of hospital-
ization compared with AF patients without OSA. The
overall hospitalization rate in ORBIT-AF patients was
high (about 48% at 2 years) and was even higher
(almost 54%) in patients with OSA. However, mortality
rates and major adverse cardiovascular events and
major bleeding were similar to the risk in patients
without OSA. Hence, no difference in major adverse
cardiovascular events was seen in patients with or
without OSA in this study, and a direct causal effect of
OSA in cardiovascular disease remains questionable.21,23
Similarly, AF did not appear to progress tomore persistent/
sustained forms more frequently in patients with OSA
compared to patients without OSA.
Table IV. Association of CPAP treatment and 2-year outcomes
Outcome
CPAP (n = 937) No CPAP (n = 687)
Unadjusted HR
(95% CI) P
Adjusted HR
(95% CI) P
No. of events
(events/100 patient-years)
No. of events
(events/100 patient-years)
All-cause death 68 (4.44) 54 (4.86) 0.92 (0.67-1.25) .58 1.10 (0.78-1.54) .60
First hospitalization (all-cause) 471 (43.9) 329 (41.9) 1.05 (0.93-1.18) .42 1.10 (0.97-1.24) .14
CV death, MI, stroke/TIA 57 (3.78) 41 (3.73) 1.02 (0.68-1.52) .94 1.15 (0.73-1.82) .55
Major bleeding 71 (4.81) 43 (3.99) 1.20 (0.85-1.71) .29 1.45 (0.99-2.11) .06
Outcome
CPAP (n = 602) No CPAP (n = 411)
Unadjusted OR
(95% CI) P
Adjusted OR
(95% CI) PNo. of events (percent) No. of events (percent)
Progression of AF type 94 (16) 75 (18) 0.74 (0.55-0.99) .04 0.66 (0.46-0.94) .02
Abbreviation: CV, Cardiovascular; MI, myocardial infarction.
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oagulation prophylaxis at baseline in ORBIT AF. This is
most likely due to the fact that patients with OSA had
more cardiovascular comorbidity (eg, hypertension and
diabetes) and therefore perceived to be at higher risk of
stroke, although their lower age and male predominance
actually led to similar CHADS2- and lower CHA2DS2-VASc
scores.
Apart from behavioral treatment (eg, weight loss,
increased physical activity), CPAP treatment is the most
common treatment for moderate-to-severe OSA.24 The
rate of CPAP usage in ORBIT-AF was 58% with only minor
differences in patient characteristics between patients
with and without CPAP treatment. Data on CPAP usage
in similar registries are, to the best of our knowledge,
lacking. However, given that CPAP treatment is primarily
indicated for treatment of moderate to severe OSA and
that the adherence to CPAP treatment is known to be
low, we believe that 58% of the patients with OSA stating
that they are “currently undergoing CPAP therapy” seems
reasonable. Although several observational studies have
indicated that CPAP treatment may be effective in
reducing the cardiovascular event rate in patients with
OSA, the observed effect in prospective/randomized
studies has at best been modest.6,21,25–27 Nonrandomized
data regarding CPAP treatment of OSA and the likelihood
of AF relapse after cardioversion indicate that CPAP is
likely beneficial.14 More recently, specific data regarding
CPAP treatment in relation to AF relapse after catheter
ablation of AF indicate that CPAP treatment may lower
the relapse rate, but randomized comparisons are lacking.10–12
In keeping with these data, a slightly smaller proportion of
patients with OSA on CPAP treatment progressed to
more sustained forms of AF in this study. However, there
were no statistically significant differences in mortality
rates and major adverse cardiovascular events between
patients with OSA treated with CPAP and those without
CPAP treatment.Limitations
These data are from a voluntary, observational study
and thus are susceptible to the limitations inherent
in such methods. These include both selection and
reporting biases. Residual measures and unmeasured
confounding may influence these findings. Given that the
number of test of primary interest was relatively limited,
adjustment for multiple comparisons was not made to
control type I error because this would have increased
the risk of type II error. The diagnosis of OSA in these
patients was made on the basis of physician report and
medical records. We did not have access to sleep study
data, including apnea-hypopnea indices. Likewise, we do
not have data on average duration of CPAP use per night
in patients on CPAP treatment. This study used 2-year
follow-up. It is possible that the differences between OSA
and non-OSA as well as between CPAP treated and
nontreated patients with OSA would have become more
evident over time. On the other hand, our study has
several strengths, including a large nationwide cohort
with regular follow-up and detailed information on
comorbid illness.
Clinical implications
The frequency of OSA in this nationwide cohort
emphasizes the importance of screening for OSA in patients
diagnosed with AF. Furthermore, once AF is identified,
these data highlight the potential role of CPAP as ameans to
prevent AF progression and decrease AF burden. The role of
CPAP in reducing AF burden is currently being evaluated in
clinical trials.
Conclusion
Nearly 1 in 5 patients with AF in our nationally
representative cohort study had OSA. Patients with OSA
have worse functional status and a higher risk of hospital-
ization than patients without OSA. However, major adverse
Figure
The figure summarizes the adjusted associations between the outcome variables and CPAP treatment in patients with OSA. Abbreviations: CL,
Confidence limit; CVD, cardiovascular death; LCL, lower confidence limit; MI, myocardial infarction; UCL, upper confidence limit.
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Volume 169, Number 5cardiovascular events and all-cause mortality did not
differ between patients with and without OSA. Similarly,
AF in patients with OSA did not appear to progress more
frequently to more persistent/sustained forms of AF. In
patientswithOSA, CPAP treatmentmay attenuate the rate of
AF progression.
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Variable List for Outcome Models
Demographics
1. Age, years
2. Race—African American/Hispanic/White/others
3. Gender—male/female
4. Level of education—some school/high school
graduate/college graduate/post graduate
5. Payor/insurance—Medicare or
Medicaid/private/others
Medical history
1. Smoking—current/recent or former/nonsmoker
2. Cancer—yes/no
3. Hypertension—yes/no
4. Osteoporosis—yes/no
5. Diabetes—yes/no
6. Hip fracture—yes/no
7. Hyperthyroidism—yes/no
8. Hypothyroidism—yes/no
9. GI bleed—yes/no
10. OSA—yes/no
11. Dialysis—yes/no
12. Hyperlipidemia—yes/no
13. Anemia—yes/no
14. Cognitive impairment/dementia—yes/no
15. Frailty—yes/no
16. Liver disease—yes/no
17. COPD—yes/no
18. Alcohol abuse—yes/no
19. Drug abuse—yes/no
Cardiovascular history
1. Family history of AF—yes/no
2. Peripheral vascular disease—yes/no
3. Sinus node dysfunction/sick sinus syndrome—yes/no
4. Stroke or TIA—yes/no
5. Congestive heart failure (CHF)—noCHF/NYHAClass
I/NYHA Class II/NYHA Class III or NYHA Class IV
6. Significant valvular disease—yes/no
7. Prior valve replacement/repair—yes/no
Coronary artery disease history
1. History of coronary artery disease—yes/no
2. Prior MI—yes/no
3. Prior CABG—yes/no
4. Any PCI—yes/no
Vital signs and AF status
1. Height, cm
2. Weight, kg
3. Heart rate, beat/min4. Diastolic blood pressure, mm Hg
5. Systolic blood pressure, mm Hg
6. Bodymass index, kg/m2 (For imputationpurpose,wewill
impute individual components which areweight, height)
7. Intraventricular conduction—RBBB/LBBB/nonspe-
cific IVCD or unknown-ventricularly paced/none
Echocardiographic assessment (TTE or TEE)
1. LVEF—normal (N50%)/mild dysfunction (N40%,
b50%)/moderate dysfunction (N30%, b40%)/severe
dysfunction (b30%)
2. LAD type—normal/mild enlargement/moderate
enlargement/severe enlargement
Laboratory data
1. eGFR (MDRD), mg/dL (For imputation purpose, we
will impute individual components which are age,
gender, race, and serum creatinine)
2. Hemotocrit, % (fill in from hemoglobin by
hemoglobin*3 if missing)
Atrial fibrillation diagnosis
1. Type of AF—first detected or new onset/paroxysmal
AF/persistent AF/permanent AF
2. EHRA score—no symptoms/mild/severe/disabling
3. Management strategy—rate control/rhythm control
4. Prior cardioversions—yes/no
5. Prior antiarrhythmic drug—yes/no
6. Catheter ablation of AF—yes/no
7. AV Node or HIS bundle ablation—yes/no
Functional status
1. Functional status—living independently/living with
assistance or resides in assisted living facility or
resides in skilled nursing home or bedbound
Provider or site
1. PI/site specialty—cardiology/electrophysiology/family
practice or internal medicineCovariates included in regression model
for each outcome
All-cause death
• Level of education, rhythm control, cognitive impair-
ment/dementia, hyperlipidemia, linear spline for eGFR
≤80 mg/dL, linear spline eGFR N80 mg/dL, LAD type,
cancer, diastolic blood pressure truncated at 70, intrav-
entricular conduction, frailty, height heart rate, hemat-
ocrit, diabetes, smoking, linear spline for systolic blood
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sex, CHF, age, and functional status
First all-cause hospitalization
• Linear spline forage≤70 years, linear spline forage N70,
years BMI, weight, osteoporosis, height, PCI, cancer, OSA,
anemia, frailty, insurance status, history of CAD, PI/Site
specialty, prior antiarrhythmic drug use, peripheral
vascular disease, functional status, linear spline for heart
rate N68 beat/min, diabetes, hematocrit, linear spline for
eGFR≤ 80mg/dL, COPD, diastolic blood pressure truncated
at 70 beat/min, EHRA score, and CHF
Composite of CVD death, stroke or non–central nervous
system embolism, TIA or MI
• AF type, diabetes, history of CAD, BMI, LAD type, sex,
height, diastolic blood pressure, AV node/HIS bundleablation, LVEF type, COPD, stroke/TIA, CHF, functional
status, eGFR and age
Major bleeding
• COPD, OSA, LAD type, cancer, functional status, level
of education, intraventricular conduction, rhythm control,
smoking status, significant valvular disease, eGFR,
insurance status, history of GI bleed, anemia,
and hematocrit
AF progression
• Catheter ablation, hypertension, congestive heart failure,
cognitive impairment/dementia, history of drug abuse,
systolic blood pressure, EHRA score, AVnode/HIS bundle
ablation, LAD type, age prior cardioversions rhythm
control, and linear spline for heart rate between 66
and 88 beat/min
